📊 CGTX Key Takeaways
Investment Thesis
Cognition Therapeutics is a pre-revenue biotech company with minimal revenue (-$10K) and substantial operating losses (-$34.1M), indicating it is in early-stage clinical development with no commercialized products. While the company maintains strong liquidity with $39.3M in cash and a 6.44x current ratio, ongoing negative cash flows of -$21.2M annually suggest the cash runway is limited to approximately 1.8 years at current burn rates, creating significant execution and dilution risk.
CGTX Strengths
- Strong liquidity position with $39.3M cash and 6.44x current ratio providing operational flexibility
- No meaningful debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk
- Stockholders equity of $36.5M provides reasonable balance sheet cushion relative to asset base
CGTX Risks
- Negative operating cash flow of -$21.2M annually with minimal revenue indicates company is pre-commercial with uncertain pathway to profitability
- Limited cash runway of approximately 1.8 years at current burn rate creates near-term financing risk and potential shareholder dilution
- High insider activity (9 Form 4 filings in 90 days) warrants monitoring for potential value destruction or significant corporate events
Key Metrics to Watch
- Cash burn rate trend and runway extension milestones
- Clinical trial progress and regulatory pathway developments
- Revenue recognition timing and commercialization success of lead programs
CGTX Financial Metrics
💡 AI Analyst Insight
The 211,550.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 6.44x current ratio provides a solid financial cushion.
CGTX Profitability Ratios
CGTX vs Healthcare Sector
How COGNITION THERAPEUTICS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CGTX Balance Sheet & Liquidity
CGTX 5-Year Financial Trend
5-Year Trend Summary: COGNITION THERAPEUTICS INC's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.86 indicates the company is currently unprofitable.
CGTX Growth Metrics (YoY)
CGTX Capital Allocation
CGTX SEC Filings
Access official SEC EDGAR filings for COGNITION THERAPEUTICS INC (CIK: 0001455365)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CGTX
What is the AI rating for CGTX?
COGNITION THERAPEUTICS INC (CGTX) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CGTX's key strengths?
Strong liquidity position with $39.3M cash and 6.44x current ratio providing operational flexibility. No meaningful debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk.
What are the risks of investing in CGTX?
Negative operating cash flow of -$21.2M annually with minimal revenue indicates company is pre-commercial with uncertain pathway to profitability. Limited cash runway of approximately 1.8 years at current burn rate creates near-term financing risk and potential shareholder dilution.
What is CGTX's revenue and growth?
COGNITION THERAPEUTICS INC reported revenue of $-10.0K.
Does CGTX pay dividends?
COGNITION THERAPEUTICS INC does not currently pay dividends.
Where can I find CGTX SEC filings?
Official SEC filings for COGNITION THERAPEUTICS INC (CIK: 0001455365) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CGTX's EPS?
COGNITION THERAPEUTICS INC has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.